NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

Sirolimus的全球市場:成長,趨勢,預測(2020年∼2025年)

Sirolimus Market - Growth, Trends And Forecast (2020 - 2025)

出版商 Mordor Intelligence Pvt Ltd 商品編碼 928074
出版日期 內容資訊 英文 105 Pages
商品交期: 2-3個工作天內
價格
Sirolimus的全球市場:成長,趨勢,預測(2020年∼2025年) Sirolimus Market - Growth, Trends And Forecast (2020 - 2025)
出版日期: 2020年03月01日內容資訊: 英文 105 Pages
簡介

Sirolimus市場在預測期間內預計將以4.1%的年複合成長率發展。又稱Rapamycin的Sirolimus,是由吸水鏈黴菌產生的大環內酯類抗生素,具有強大的免疫抑制活性。

本報告提供全球Sirolimus市場調查,市場概要,各用途、各地區的市場規模的變化與預測,市場趨勢,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場成長要素
    • 移植率和文明病的盛行率增加
    • 各種適應症的有潛力開發平台
  • 阻礙市場要素
    • Sirolimus的副作用
  • 波特的五力分析

第5章 市場細分化

  • 各用途
    • 器官移植排斥反應
    • 淋巴管平滑肌瘤症
    • Sirolimus塗層球囊、導管
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲地區
    • 南美

第6章 競爭情形

  • 企業簡介
    • Pfizer, Inc
    • Biocon
    • Dr. Reddy's Laboratories Ltd
    • Concept Medical, Inc
    • Stentys SA
    • Torrent Pharmaceuticals Ltd
    • Zydus Cadila
    • Intas Pharmaceuticals Ltd
    • Concord Biotech

第7章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 68296

The Sirolimus Market is expected to register a CAGR of 4.1% during the forecast period. Sirolimus also known as rapamycin is a macrolide antibiotic produced by Streptomyces hygroscopicus with potent immunosuppressive activity. It acts by impairing cytokine-induced lymphocyte proliferation. Sirolimus is primarily used as an immunosuppressant for patients undergoing organ transplantation, can also be used as a chemotherapeutic agent.

Sirolimus is unique from the other calcineurin inhibitors such as tacrolimus and cyclosporine, in its targeting of mTOR. Mammalian target of rapamycin (mTOR) coordinates cell growth and cell proliferation and its signalling pathway is implicated in the development of various conditions such as neurological diseases, cancer, genetic disorders and obesity. As Sirolimus targets mTOR which involve in various critical biological functions, and it has many treatment applications beyond organ transplantation. Apart from organ transplantation application, this drug can be used in coating coronary stents for preventing rejection of transplanted organs by the body system and used for treating lymphagioleiomyomatosis, which is a rare lung ailment.

According to the World Health Organization (WHO), approximately 100,800 solid organ transplants are performed every year worldwide among them 69,400 kidney transplants, 20,200 liver transplants, 5,400 heart transplants, 3,400 lung transplants and 2,400 pancreas transplants.

Increasing transplantation rates and occurrence of lifestyle-related diseases, promising pipeline for different indications and improving healthcare infrastructure are the key driving factors of sirolimus market.

Key Market Trends

Organ Transplant Rejection Segment is Expected to Hold a Major Market Share in the Sirolimus Market

  • Organ transplantation is a medical procedure used to replace a damaged or missing organ by removing it from the donor and placing in the body of the recipient. In order to lower the body's ability to reject a transplanted organ immunosuppressants or anti-rejection drugs such as sirolimus are used.
  • According to the U.S. Department of Health and Human Services and Health Resources and Services Administration, more than 113,000 people needed transplants as of 2019 and 36,528 transplants were performed in the year 2018.
  • Increasing transplantation rates, occurrence of lifestyle-related diseases, and technological advancements in organ transplantation are the key driving factors in the organ transplant rejection segment.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global sirolimus market due to high volume of organ transplants, rising incidence of chronic diseases and presence of favorable reimbursement policies in this region. According to the Disease Control and Prevention (CDC), the most common transplanted organs in the United States are kidney, liver, heart, lungs, pancreas and intestine. On an average every day, there are about 75,000 people on active waiting list for organ transplantation. Furthermore, technological advancements in organ transplantation, increasing healthcare spending and presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Sirolimus Market is fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Pfizer, Inc, Biocon, Dr. Reddy's Laboratories Ltd, Concept Medical, Inc, Stentys SA, Torrent Pharmaceuticals Ltd, Zydus Cadila, Intas Pharmaceuticals Ltd and Concord Biotech.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Transplantation Rates and Prevalence of Lifestyle-related Diseases
    • 4.2.2 Promising Pipeline for Different Indications
  • 4.3 Market Restraints
    • 4.3.1 Adverse Effects Associated with Sirolimus
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Application
    • 5.1.1 Organ Transplant Rejection
    • 5.1.2 Lymphangioleiomyomatosis
    • 5.1.3 Sirolimus Coated Balloons and Catheter Devices
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle-East and Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle-East and Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Pfizer, Inc
    • 6.1.2 Biocon
    • 6.1.3 Dr. Reddy's Laboratories Ltd
    • 6.1.4 Concept Medical, Inc
    • 6.1.5 Stentys SA
    • 6.1.6 Torrent Pharmaceuticals Ltd
    • 6.1.7 Zydus Cadila
    • 6.1.8 Intas Pharmaceuticals Ltd
    • 6.1.9 Concord Biotech

7 MARKET OPPORTUNITIES AND FUTURE TRENDS